Supernus Pharmaceuticals, Inc. announced Intangible asset impairment charges for the quarter ended December 31, 2023. For the quarter, the company reported Intangible asset impairment charges of $20,189,000.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.44 USD | -2.76% | +0.03% | +4.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.63% | 1.72B | |
+8.12% | 72.03B | |
-10.86% | 5.14B | |
+46.43% | 4.6B | |
+5.38% | 3.96B | |
-16.20% | 2.5B | |
+21.01% | 2.43B | |
-26.20% | 2.32B | |
+19.92% | 2.18B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023